287 related articles for article (PubMed ID: 9949863)
1. Serotonin in migraine: theories, animal models and emerging therapies.
Johnson KW; Phebus LA; Cohen ML
Prog Drug Res; 1998; 51():219-44. PubMed ID: 9949863
[TBL] [Abstract][Full Text] [Related]
2. Neurogenic inflammation in the context of migraine.
Williamson DJ; Hargreaves RJ
Microsc Res Tech; 2001 May; 53(3):167-78. PubMed ID: 11301492
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of migraine--new insights.
Hargreaves RJ; Shepheard SL
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S12-9. PubMed ID: 10563228
[TBL] [Abstract][Full Text] [Related]
4. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
[TBL] [Abstract][Full Text] [Related]
6. Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation.
Johnson KW; Nelson DL; Dieckman DK; Wainscott DB; Lucaites VL; Audia JE; Owton WM; Phebus LA
Cephalalgia; 2003 Mar; 23(2):117-23. PubMed ID: 12603368
[TBL] [Abstract][Full Text] [Related]
7. Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
[TBL] [Abstract][Full Text] [Related]
8. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
9. The biology of serotonin receptors: focus on migraine pathophysiology and treatment.
Hamel E
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S2-6. PubMed ID: 10563226
[TBL] [Abstract][Full Text] [Related]
10. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis.
Ramadan NM; Skljarevski V; Phebus LA; Johnson KW
Cephalalgia; 2003 Oct; 23(8):776-85. PubMed ID: 14510923
[TBL] [Abstract][Full Text] [Related]
11. Is selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
[TBL] [Abstract][Full Text] [Related]
12. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
13. Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats.
Ma QP; Hill R; Sirinathsinghji D
Eur J Neurosci; 2001 Jun; 13(11):2099-104. PubMed ID: 11422450
[TBL] [Abstract][Full Text] [Related]
14. Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis.
Cutrer FM; Yu XJ; Ayata G; Moskowitz MA; Waeber C
Neuropharmacology; 1999 Jul; 38(7):1043-53. PubMed ID: 10428423
[TBL] [Abstract][Full Text] [Related]
15. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
[TBL] [Abstract][Full Text] [Related]
16. New insights into the molecular actions of serotonergic antimigraine drugs.
Durham PL; Russo AF
Pharmacol Ther; 2002; 94(1-2):77-92. PubMed ID: 12191595
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia facilitates neurogenic dural plasma protein extravasation in mice: a novel animal model for migraine pathophysiology.
Hunfeld A; Segelcke D; Bäcker I; Mecheri B; Hemmer K; Dlugosch E; Andriske M; Paris F; Zhu X; Lübbert H
Sci Rep; 2015 Dec; 5():17845. PubMed ID: 26644235
[TBL] [Abstract][Full Text] [Related]
18. 5-HT7 receptors are involved in neurogenic dural vasodilatation in an experimental model of migraine.
Wang X; Fang Y; Liang J; Yan M; Hu R; Pan X
J Mol Neurosci; 2014; 54(2):164-70. PubMed ID: 24584680
[TBL] [Abstract][Full Text] [Related]
19. On serotonin and migraine: a clinical and pharmacological review.
Ferrari MD; Saxena PR
Cephalalgia; 1993 Jun; 13(3):151-65. PubMed ID: 8395342
[TBL] [Abstract][Full Text] [Related]
20. The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.
Williamson DJ; Hill RG; Shepheard SL; Hargreaves RJ
Br J Pharmacol; 2001 Aug; 133(7):1029-34. PubMed ID: 11487512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
